This Animal Health Stock Tanks on Earnings. Pig and Chicken Medication Revenue Slumps.

Core Viewpoint - Zoetis has significantly reduced its full-year financial outlook, indicating challenges in the market and potential impacts on future performance [1] Financial Performance - The company has adjusted its revenue forecast, now expecting between $7.45 billion and $7.55 billion, down from a previous estimate of $7.55 billion to $7.65 billion [1] - Zoetis anticipates adjusted earnings per share (EPS) in the range of $3.05 to $3.15, a decrease from the earlier guidance of $3.15 to $3.25 [1] Market Challenges - The revision in outlook is attributed to various market pressures, including changes in demand and pricing dynamics within the veterinary pharmaceutical sector [1] - The company is facing increased competition and pricing pressures that are affecting its sales growth [1]